Objectives. Parenteral L-arginine will improve myocardial ischemia in patients with obstructive coronary artery disease.
Blood vessel tone is modulated by balanced actions of vasoconstricting and dilating compounds that are either circulating or locally synthesized in the vascular wall. Predominance of vasoconstrictor influences, especially in the presence of atherosclerotic coronary arterial narrowing, leads to further restriction of myocardial blood flow and exacerbation of ischemia (1) . Important vasoconstrictors include catecholamines, angiotensin II and endothelin, and their action appears to be counterbalanced by locally generated endothelium-derived vasodilators such as nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarizing factor. Nitric oxide, considered to be the predominant endothelium-derived relaxing factor, is constitutively synthesized by the action of a calciumcalmodulin-sensitive enzyme NO synthase on L-arginine (2) . Nitric oxide diffuses luminally into the blood stream and inhibits platelet aggregation and adhesion, and penetrates abluminally into the vascular smooth muscle to cause vasodilation. Nitric oxide activity is impaired in the coronary and peripheral vasculature of patients with atherosclerosis and those with risk factors for atherosclerosis (3) (4) (5) (6) (7) (8) . This abnormality is associated with paradoxical vasoconstriction or failure of appropriate vasodilation of blood vessels in response to physiologic stress (9 -12) that in turn may exacerbate myocardial ischemia in patients with obstructive coronary artery disease. Therapies designed to improve NO bioavailability would therefore be expected to increase vascular dilator tone at rest and during exercise and thereby ameliorate myocardial ischemia.
One strategy widely tested in recent years to improve vascular NO activity is the replenishment of L-arginine, the substrate for NO synthesis. L-arginine administration improved abnormal endothelium-dependent vasodilation in hypercholesterolemia (13) (14) (15) . Intraarterial L-arginine also improved abnormal endothelium-dependent responses in the coronary vasculature of patients with atherosclerosis and inhibited the abnormal coronary constriction observed with pacing (16 -18) . A recent report demonstrated vasodilation of coronary stenoses with intracoronary L-arginine (19) . On the basis of these observations, we hypothesized that parenteral L-arginine, by improving NO bioavailability, will improve myocardial ischemia in patients with obstructive atherosclerotic coronary artery disease by abrogating coronary constriction during stress.
Methods
Patients. We studied 22 patients, 19 men and 3 women (mean age 63.5 Ϯ 2 years) with stable symptoms, angiographically documented coronary artery disease and exercise-induced ST-segment depression. Patients had undergone previous treadmill exercise testing on at least two or more occasions and had demonstrable ischemia on radionuclide testing. Mean serum cholesterol was 243 Ϯ 12 mg/dl, seven patients were hypertensive, six diabetic and four were current smokers or had smoked in the past year. None had suffered from unstable angina or myocardial infarction in the 3-month period before the study, and all patients were free of symptoms of heart failure. Patients gave informed consent and the protocol was approved by the Investigational Review Board of the National Heart, Lung and Blood Institute.
Protocol. On the first day, an intraarterial cannula was introduced under local anesthesia in the brachial artery of the nondominant arm. After 1-h rest, dextrose 5% (D5W) was given intravenously at 2 ml/min and patients were exercised on the treadmill, employing the National Institutes of Health Combined protocol (20) . Blood pressure, heart rate and a 12-lead electrocardiogram were recorded every 30 s to accurately determine the ischemic threshold (heart rate and blood pressure at the onset of 1-mm ST-segment depression). Exercise was terminated for moderate intensity chest pain, limiting dyspnea, Ն3 mm ST-segment depression, hypertension or excessive fatigue.
After a 3-h recovery period on day 1, patients had determination of forearm endothelial function with intraarterial acetylcholine (ACH). This was followed by a double-blind randomized intravenous infusion of either L-arginine or D-arginine (Sigma Chemical) at 5 mg/kg/min for 20 min. In our preliminary experience, the infusion of 10 mg/kg/min arginine caused nausea in some patients. After 20 min of arginine infusion, determination of forearm endothelial function using intraarterial ACH was repeated. After this and approximately 30 min after commencing arginine infusion, treadmill exercise testing was performed and the infusion was terminated after the end of exercise.
The following day, repeat measurement of endothelial function was performed with intraarterial ACH and these measurements were repeated 20 min after either intravenous L-arginine or D-arginine. At the end of these measurements treadmill exercise testing was repeated while continuing infusion of intravenous arginine, as on the previous day.
Measurement of forearm endothelial function. All studies were performed in a quiet room with a temperature of approximately 22°C, as previously described (21, 22) . Patients were asked to refrain from drinking alcohol or beverages containing caffeine and from smoking for Ն24 h before studies. A needle was inserted in the brachial artery of the nondominant arm that was slightly elevated above the level of the right atrium, and a mercury-filled Silastic strain gauge was placed on the widest part of the forearm. The strain gauge was connected to a plethysmograph (model EC-4, D. E. Hokanson, Issaquah, Washington) calibrated to measure the percent change in volume; the plethysmograph in turn was connected to a chart recorder to record the forearm flow measurements. For each measurement, a cuff placed on the upper arm was inflated to 40 mm Hg with a rapid cuff inflator (model E-10, Hokanson) to occlude venous outflow from the extremity. A wrist cuff was inflated to suprasystolic pressures 1 min before each measurement to exclude hand circulation. Flow measurements were recorded for approximately 7 s every 15 s; 7 readings were obtained for each mean value.
Basal measurements were obtained during intraarterial infusion of 5% dextrose solution at 1 ml/min. Forearm flows were then measured after the infusion of intraarterial ACH at 30 and 60 g/min. Each dose was infused for 5 min and forearm flow was measured during the last 2 min of the infusion. Measurements were repeated 20 min after intravenous L-arginine or D-arginine on both days.
Plasma arginine, insulin, prolactin and glucose measurements. Before the study and after 20-min infusions of L-and D-arginine, blood sampling was performed in 10 patients to measure serum glucose, prolactin, insulin and arginine levels.
Statistical analysis. Data are expressed as mean Ϯ SEM. The difference between means was tested with paired or unpaired Student's t test as appropriate. All tests were twosided and a p Ͻ 0.05 was considered statistically significant. The hemodynamic changes during exercise and the dose response curves with ACH before and after L-and D-arginine were compared using a two-way repeated measures analysis of variance (ANOVA) (23) with appropriate interaction terms. Figure 1 demonstrates the effect of both arginine enantiomers on forearm vascular endothelial function. Forearm vasodilation occurred with both intravenous L-and Darginine; compared to baseline, forearm blood flow increased by 33% Ϯ 6% with L-arginine and 38% Ϯ 7% with D-arginine, and forearm vascular resistance decreased by 28% Ϯ 5% and 21% Ϯ 5%, respectively (all p Ͻ 0.001). There was no difference between the magnitude of vasodilation with Dcompared to L-arginine. Mean arterial pressure remained unchanged with both drugs; Ϫ2% Ϯ 1% (p ϭ 0.1) change with L-arginine and 2% Ϯ 1% (p ϭ 0.3) change with D-arginine.
Results

Effects of intravenous D-and L-arginine on endothelial function.
Acetylcholine produced progressive forearm microvascular dilation that was enhanced by both L-arginine (p Ͻ 0.0001, ANOVA) and D-arginine (p Ͻ 0.0001, ANOVA) (Fig. 1) ; thus, at the peak dose of ACH, forearm blood flow increased from 17.4 Ϯ 2.2 ml/min/100 ml to 21.5 Ϯ 2.3 ml/min/100 ml (p ϭ 0.01) with L-arginine and from 14.4 Ϯ 1.9 to 19.4 Ϯ 2.4 ml/min/100 ml (p Ͻ 0.001) with D-arginine. Because of the change in resting blood flow with L-and D-arginine, we also calculated the flow increment, compared to baseline, with ACH before and after arginine (Fig. 2) . This analysis demonstrated a significant further enhancement (above resting levels) in ACH-induced vasodilation with both L-and D-arginine. There was no change in arterial pressure during administration of ACH either before or after L-arginine or D-arginine.
Effects of intravenous D-and L-arginine on exercise hemodynamics. There was no alteration in heart rate, systolic, diastolic or mean arterial pressures with either L-arginine or D-arginine at rest (Fig. 3) . During treadmill exercise there was also no significant change in heart rate, systolic blood pressure or rate-pressure product achieved at each stage during D5W, L-arginine or D-arginine administration (Fig. 3) . Peak exercise duration remained unchanged, and the heart rate, blood pressure and rate-pressure product achieved at peak exercise were unchanged during D-and L-arginine therapy and D5W administration (Fig. 4) . Finally, there was no significant change in the duration of exercise or heart rate and blood pressure at 1-mm ST-segment depression during L-arginine or D-arginine therapy compared to control exercise with D5W.
Subgroup analysis. Previous studies have demonstrated improvement in peripheral vascular endothelial function with L-arginine in subjects with hypercholesterolemia and in those with more severe coronary vascular endothelial dysfunction (21, 23) . We therefore analyzed two subgroups, those with more severe vascular endothelial dysfunction and patients with hypercholesterolemia, to investigate whether arginine was of greater benefit in these subsets.
Patients were divided into two equal-sized groups with either "depressed" or "normal" endothelial function based on that peak response to ACH. Both groups of patients had improvement of ACH-mediated vasodilation with L-and D-arginine (Fig. 5) . During treadmill exercise testing, there was no change in the ischemic threshold or hemodynamics at peak exercise with L-arginine or D-arginine compared to D5W in either patients with depressed or normal endothelial function (Fig. 5) .
Finally, responses in patients with hypercholesterolemia (total cholesterol Ͼ250 mg/dl, mean 293 Ϯ 10, n ϭ 11) were compared to those with lower serum cholesterol levels (Ͻ250 mg/dl, mean 193 Ϯ 7, n ϭ 11). Both hypercholesterolemic and normocholesterolemic patients had improvement of ACHmediated forearm vasodilation with L-and D-arginine, with no difference in the magnitude of improvement between the two arginine enantiomers in either subgroup (p ϭ 0.38 in normocholesterolemic and p ϭ 0.34 in hypercholesterolemic patients, D-vs. L-arginine). There was no change in the ischemic threshold or hemodynamics at peak exercise with either L-arginine or D-arginine compared to D5W either in patients with or in patients without hypercholesterolemia. Serum arginine, prolactin, glucose and insulin levels (Table 1). Serum arginine level increased from 17.9 Ϯ 2 to 406 Ϯ 64 mol/dl (p Ͻ 0.001) with L-arginine administration for 30 min and from 16.5 Ϯ 4 to 519 Ϯ 64 mol/dl (p Ͻ 0.001) with intravenous D-arginine. This was associated with a simultaneous increase in serum prolactin and insulin levels with both L-and D-arginine. There was no significant difference between the magnitude of increase in serum insulin (85% Ϯ 22% vs. 108% Ϯ 35%) or prolactin (207% Ϯ 29% vs. 191% Ϯ 49%) with L-arginine or D-arginine, respectively. Glucose levels remained unchanged during both infusions (Table 1) .
Discussion
Our study demonstrates that both enantiomers of arginine, when administered intravenously to patients with atherosclerotic coronary artery disease, produce forearm vasodilation at rest and enhance endothelium-dependent dilation in response to ACH. Despite improvement of vascular function at rest and with pharmacologic stimulation, there is no significant amelioration of myocardial ischemia during exercise.
Arginine and endothelial function. Demonstration of enhanced NO production from the vasculature of hypercholesterolemic and atherosclerotic animals with endothelial dysfunction has been a stimulus for using L-arginine in human studies (13, 14) . Peripheral arteriolar dilation in response to ACH improved with intraarterial L-arginine but not Darginine in normal subjects, but not in those with hypertension, hypercholesterolemia or atherosclerosis (21,24 -27 ). In contrast, intravenous L-arginine but not D-arginine improved forearm dilation in hypercholesterolemic subjects in response to methacholine (14) . In the coronary vasculature, improvement in ACH responses in hypercholesterolemic and atherosclerotic patients with intraarterial L-arginine could not be reproduced with intraarterial D-arginine (16 -18) . Finally, oral arginine also improved brachial artery flow-mediated dilation, a surrogate measure of endothelial cell integrity in hypercholesterolemic subjects, but not in normal individuals (28) . Taken together, these studies suggest that the route of administration of arginine, the vascular bed and the specific causes leading to endothelial dysfunction may, to some extent, influence the response of arginine in vivo.
It is noteworthy that non-stereo-specific arteriolar and venous dilation accompanied by hypotension occurs in normal subjects at high parenteral concentrations of both L-and D-arginine (29 -31) . We observed peripheral vasodilation at somewhat lower concentration in patients with atherosclerosis in whom blood pressure remained unchanged, suggesting that either reflex constriction occurred in other vascular beds or there was a simultaneous increase in cardiac output (30) . Of interest, heart rate also remained unchanged, indicating that there was no systemic compensation for the mild peripheral vasodilation observed with arginine. Surprisingly, both L-and D-arginine produced enhancement of ACH-mediated forearm vasodilation to a similar extent, a finding present in patients throughout the range of responses to ACH. This contrasts with previous observations where intravenous L-arginine but not D-arginine improved methacholine responses in hypercholesterolemic patients (14) . These differences might be explained either because the serum arginine levels were lower than those achieved in our study, or fewer patients were studied with D-arginine or methacholine and not ACH was used as a probe for testing endothelial function in that study.
Mechanisms underlying arginine-mediated improvement in endothelial function. L-arginine but not D-arginine is a substrate for NO synthesis. L-arginine is catalyzed by the action of NO synthase to yield NO and L-citrulline (32). The K m for L-arginine in normal endothelial cells (2.9 mol/liter) is several magnitudes lower than the intracellular concentrations of L-arginine (0.8 to 2 mmol/liter), which makes it unlikely that substrate deficiency is limiting for NO synthesis (33) . Indeed, in vitro, improvement with L-arginine can only be seen when its levels are depleted (34) . In contrast, parenteral arginine in vivo increases vascular NO activity (29, 30) . Although it is believed that endothelial dysfunction in hypercholesterolemia, diabetes and atherosclerosis is due to inactivation of NO by oxygen-free radicals, it is unlikely that substrate limitation occurs even in these circumstances of increased NO turnover (35) . Furthermore, were this to be the mechanism, only L-arginine but not D-arginine would be expected to produce improvement of the ACH response.
There are several other proposed mechanisms whereby L-arginine may improve endothelial function. These include: 1) reversal of inhibitory effects of L-glutamine on L-arginine bioavailability (34), 2) counteracting the inhibitory effects of asymmetric dimethyl arginine (ADMA), a naturally occurring inhibitor of L-arginine (36 -38), 3) its anti-oxidant actions (38,39), 4) stimulation of insulin release (40 -44) and 5) nonenzymatic and non-stereo-specific generation of NO by arginine (45) . The heart rate, mean arterial blood pressure, rate-pressure product and the duration of exercise at 1-mm ST-segment depression during treadmill exercise testing with dextrose 5% (D5W), L-arginine and D-arginine. There were no significant differences between the treatments by two-way repeated measures ANOVA.
Because it is clear that the actions of arginine in reversing the inhibitory effects of L-glutamine, superoxide anions and ADMA are all specific for the L-enantiomer, it is likely that our observations of non-stereo-specific improvement in ACH responses are either a result of hormonal stimulation, in particular of insulin, or due to NO generation by the nonenzymatic pathway.
Myocardial ischemia and coronary artery disease. Myocardial ischemia in patients with obstructive coronary artery disease is believed to be primarily due to the myocardial oxygen demand during exercise outstripping coronary blood flow delivery across the atherosclerotic narrowing. However, overwhelming evidence indicates that coronary vasomotion importantly modifies the ease with which myocardial ischemia occurs (1). Thus, increased coronary vascular tone can sometimes dramatically reduce coronary blood flow delivery, exacerbating myocardial ischemia. Vasoconstriction or failure of normal vasodilation during physiologic stress of the coronary vasculature in the presence of atherosclerosis and risk factors for atherosclerosis, is believed to be secondary to the development of endothelial dysfunction and reduced NO bioavailability during stress (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Using L-N G monomethyl arginine (L-NMMA), a specific antagonist of NO synthesis, it was shown that the deficiency in NO activity during stress accounted for the abnormal vasodilation during atrial pacing of the coronary circulation and during hyperemia in the peripheral circulation (24, 46) . Based on these findings, we hypothesized that improvement of endothelial NO activity with parenteral L-arginine, by abrogating vasoconstriction during stress, will ameliorate myocardial ischemia. Other effects of arginine, including reduction in viscosity and inhibition of platelet activation, may theoretically have contributed to the beneficial effects that were anticipated (29, 47) .
Despite producing baseline dilation and improving endothelium-dependent responses, there was no improvement (18) . Limitations. We have not measured the forearm vascular responses to an endothelium-independent vasodilator to confirm whether the observed improvement with arginine was specific for endothelial function and did not extend to the vascular smooth muscle. However, many previous studies have shown that neither L-arginine nor D-arginine improve sodium nitroprusside responses (14, 24) . Because of the double-blind nature of the study design, we were unable to test a range of arginine dosages. We selected our infusion rate based on previous studies demonstrating improvement of vascular endothelial function with doses of L-arginine between 0.5 and 1.0 mg/kg/min.
Our findings cannot be extended to other subgroups of patients with myocardial ischemia, such as variant angina, Syndrome X or unstable angina, where both vasoconstriction and platelet activation are major pathophysiologic etiologic factors, and may not be applicable to spontaneous ischemic episodes. Inhibition of platelet aggregation and coronary vasodilation with L-arginine could be of therapeutic benefit in these conditions. Conclusions. Our study demonstrates non-enantiomerspecific improvement of peripheral vascular endothelial function with arginine, an effect that is likely to be due either to stimulation of insulin-dependent NO release or by nonenzymatic NO generation by parenteral D-and L-arginine. Acute administration of arginine did not improve myocardial ischemia during stress in patients with stable coronary artery disease. Whether long-term oral therapy will achieve this goal and whether parenteral arginine will be beneficial in other acute ischemic syndromes needs to be explored further. 
